[SPECIFICS OF INHALED ILOPROST PHARMACODYNAMICS IN PATIENTS WITH SEVERE LEFT VENTRICULAR SYSTOLIC DYSFUNCTION]

Area of Science:

• Cardiology
• Pulmonary Medicine
• Pharmacology

Context:

• Pulmonary hypertension (PH) in patients with left ventricular systolic dysfunction presents complex hemodynamic challenges.
• Heart failure (NYHA class III-IV) with PH requires effective therapeutic strategies.
• Candidates for heart transplantation often have severe cardiac and pulmonary compromise.

Purpose:

• To investigate the hemodynamic effects of inhaled iloprost in patients with PH and left ventricular systolic dysfunction.
• To assess changes in pulmonary and systemic hemodynamics following inhaled iloprost administration.
• To evaluate the impact on cardiac performance indicators such as stroke volume index and pulmonary vascular resistance.

Summary:

• Inhaled iloprost (20 micrograms) was administered to 39 patients with severe heart failure and PH.
• Significant reductions were observed in mean pulmonary artery pressure (PAPmean) and pulmonary vascular resistance (PVR).
• Systemic vascular resistance (SVR) decreased, while stroke volume index (SVI) increased, indicating improved cardiac output and reduced afterload.

Impact:

• Inhaled iloprost demonstrated significant pulmonary and systemic hemodynamic improvements in this patient cohort.
• Favorable alterations in left ventricular preload and afterload contributed to enhanced cardiac performance.
• The findings suggest inhaled iloprost as a potential therapeutic option for managing hemodynamics in severe heart failure with PH.